Long-term transgene expression in the central nervous system using DNA nanoparticles

Area of Science:

• Neuroscience
• Biotechnology
• Gene Delivery

Background:

• Gene therapy requires efficient and safe delivery methods for the central nervous system.
• Current methods like naked DNA injection show limited efficacy and short duration.
• Developing novel non-viral vectors is crucial for CNS gene delivery.

Purpose of the Study:

• To demonstrate proof of concept for compacted plasmid DNA delivery to the central nervous system.
• To evaluate the efficacy and duration of transgene expression following intracerebral injection.
• To assess the safety profile, including brain inflammation, of this novel delivery system.

Main Methods:

• Plasmid DNA was compacted using polyethylene glycol-substituted lysine 30-mer peptides, forming nanoparticles (8-11 nm).
• Intracerebral injections of compacted DNA and naked DNA were performed in the striatum.
• Transgene expression was quantified using bioluminescent imaging (BLI) and GDNF protein levels.

Main Results:

• Compacted DNA nanoparticles achieved significantly higher transgene expression (over 100-fold) compared to naked DNA.
• Sustained transgene expression was observed in both neurons and glia for up to 8 weeks.
• Intrastriatal injection of pGDNF resulted in significant glial cell line-derived neurotrophic factor (GDNF) overexpression.
• Minimal brain inflammation was detected in animals treated with compacted DNA.

Conclusions:

• Compacted plasmid DNA nanoparticles represent a promising non-viral vector for efficient gene delivery to the central nervous system.
• This method offers a significant improvement over naked DNA for achieving long-term transgene expression in the brain.
• The technology shows potential for therapeutic applications requiring sustained gene expression, such as in neurodegenerative diseases.